This session is designed to update the learner on recent advances and emerging therapies in the treatment of metastatic melanoma. Guideline recommended therapy will be presented with an emphasis on the key clinical trials that inform treatment decisions and the role of molecular testing in the treatment paradigm. Specific treatment considerations for patients with brain metastasis will be reviewed. Oral targeted therapy and immunotherapy are associated with unique adverse effects. Early recognition and management are critical to aiding with therapy compliance and improving patient’s quality of life. This session will review key adverse effects of melanoma therapy, summarize monitoring parameters, and outline strategies to management adverse effects.
Learning Objectives:
Summarize the guideline-recommended treatment of metastatic melanoma including the results of key clinical trials for the use of immunotherapy and BRAF/MEK inhibitors
Describe treatment considerations for patients with brain metastasis from melanoma
Identify monitoring and management strategies for adverse effects associated with systemic therapy for metastatic melanoma